Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis

  • Palomo Irigoyen, Marta
  • Pérez Andrés, Encarni
  • Iruarrizaga Lejarreta, Marta
  • Barreira Manrique, Adrián
  • Tamayo Caro, Miguel
  • Vila Vecilla, Laura
  • Moreno Cugnon, Leire
  • Beitia, Nagore
  • Medrano, Daniela
  • Fernández Ramos, David
  • Lozano, Juan José
  • Okawa, Satoshi
  • Lavín, José L.
  • Martín Martín, Natalia
  • Sutherland, James D.
  • Gutiérez de Juan, Virginia
  • González López, Monika
  • Macías Cámara, Nuria
  • Mosén Ansorena, David
  • Laraba, Liyam
  • Hanemann, C. Oliver
  • Ercolano, Emanuela
  • Parkinson, David B.
  • Schultz, Christopher W.
  • Araúzo Bravo, Marcos J.
  • Ascensión, Alex M.
  • Gerovska, Daniela
  • Iribar López, Haizea
  • Izeta Permisán, Ander
  • Pytel, Peter
  • Krastel, Philipp
  • Provenzani, Alessandro
  • Seneci, Pierfausto
  • Carrasco, Ruben D.
  • Del Sol, Antonio
  • Martínez Chantar, María Luz
  • Barrio Olano, María Rosa
  • Serra, Eduard
  • Lazaro, Conxi
  • Flanagan, Adrienne M.
  • Gorospe, Myriam
  • Ratner, Nancy
  • Aransay Bañares, Ana María
  • Carracedo Pérez, Arkaitz
  • Varela Rey, Marta
  • Woodhoo, Ashwin
Cancer cells can develop a strong addiction to discrete molecular regulators, which control the aberrant gene expression programs that drive and maintain the cancer phenotype. Here, we report the identification of the RNA-binding protein HuR/ELAVL1 as a central oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of the Schwann cell lineage. HuR was found to be highly elevated and bound to a multitude of cancer-associated transcripts in human MPNST samples. Accordingly, genetic and pharmacological inhibition of HuR had potent cytostatic and cytotoxic effects on tumor growth, and strongly suppressed metastatic capacity in vivo. Importantly, we linked the profound tumorigenic function of HuR to its ability to simultaneously regulate multiple essential oncogenic pathways in MPNST cells, including the Wnt/beta-catenin, YAP/TAZ, RB/E2F, and BET pathways, which converge on key transcriptional networks. Given the exceptional dependency of MPNST cells on HuR for survival, proliferation, and dissemination, we propose that HuR represents a promising therapeutic target for MPNST treatment., This work was funded by grants to AW from the Spanish Association Against Cancer (AECC; JP Vizcaya); Spanish Ministry of Science, Innovation and Universities (MCIU)/Agencia Estatal de Investigacion (AEI)/European Regional Development Fund (FEDER), European Union (EU) (Subprograma Ramon y Cajal RYC2010-06901; Proyectos Retos Investigacion RTI2018-097503-B-I00, SAF2015-65360-R; Proyectos Explora Ciencia SAF2015-72416-EXP; Proyectos Europa Excelencia SAF2015-62588-ERC); the BBVA Foundation; Basque Department of Industry, Tourism and Trade (Elkartek) and Education (PI2013-46); Fundacion Vasca de Innovacion e Investigacion Sanitarias EiTB Maratoia (BIO13/CI/015); the Neurofibromatosis Therapeutic Acceleration Program; and the European Research Council (consolidator grant under the EU's Horizon 2020 research and innovation programme; grant agreement 865157). MVR is grateful for the support of a 2017 Leonardo Grant for Researchers and Cultural Creators (BBVA Foundation), Accion Estrategica Ciber Emergentes 2018 (Ciberehd-ISCIII), and Gilead Sciences International Research Scholars Program in Liver Disease. The work of AC is supported by the Basque Department of Industry, Tourism and Trade (Elkartek) and Education (IKERTALDE IT1106-16); the BBVA Foundation; the MCIU/AEI (SAF2016-79381-R [FEDER/EU]; Severo Ochoa Excellence Accreditation SEV-2016-0644; Excellence Networks SAF20168-1975-REDT); the European Training Networks Project (H2020-MSCA-ITN-308 2016 721532); the AECC (IDEAS175CARR, GCTRA18006CARR); La Caixa Foundation (HR17-00094); and the European Research Council (Starting Grant 336343, PoC 754627). MG was supported by the Intramural Research Program of the National Institute on Aging, NIH. MPI is grateful for the support of the Basque Government of Education fellowship. MTC is grateful for the support of "Ayudas para contratos predoctorales para la formacion de doctores" (MCIU/AEI/FEDER, EU). COH acknowledges funding from Brain Tumour Research. RB acknowledges MCIU/AEI/FEDER, EU (BFU2014-52282-P and BFU2017-84653-P). ES and CL are supported by the Carlos III National Health Institute funded by FEDER funds - a way to build Europe (CIBERONC) and the Government of Catalonia (2017SGR496). MLM-C acknowledges support from MCIU/AEI/FEDER, EU (SAF2017-87301-R); Asociacion Espanola Contra El Cancer (AECC); AECC Canceres Raros; BBVA Biomedicina (UMBRELLA); and La CAIXA Foundation (LCF/PR/HP17/52190004). AP was supported by Associazione Italiana Ricerca sul Cancro (AIRC; IG 2018 Id.21548). CIBERehd is funded by the Instituto de Salud Carlos III. We thank MCIU for the Severo Ochoa Excellence Accreditation (SEV-2016-0644).
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis

  • Palomo Irigoyen, Marta
  • Pérez Andrés, Encarni
  • Iruarrizaga Lejarreta, Marta
  • Barreira Manrique, Adrián
  • Tamayo Caro, Miguel
  • Vila Vecilla, Laura
  • Moreno Cugnon, Leire
  • Beitia, Nagore
  • Medrano, Daniela
  • Fernández Ramos, David
  • Lozano Salvatella, Juan José
  • Okawa, Satoshi
  • Lavín, José L.
  • Martín Martín, Natalia
  • Sutherland, James David
  • Guitiérez de Juan, Virginia
  • González López, Monika
  • Macías Cámara, Nuria
  • Mosén Ansorena, David
  • Laraba, Liyam
  • Hanemann, C. Oliver
  • Ercolano, Emanuela
  • Parkinson, David B.
  • Schultz, Christopher W.
  • Araúzo Bravo, Marcos J.
  • Ascensión, Alex M.
  • Gerovska, Daniela
  • Iribar, Haizea
  • Izeta, Ander
  • Pytel, Peter
  • Krastel, Philipp
  • Provenzani, Alessandro
  • Seneci, Pierfausto
  • Carrasco, Ruben D.
  • Sol, Antonio Del
  • Martínez Chantar, Maria Luz
  • Barrio, Rosa
  • Serra Arenas, Eduard
  • Lázaro García, Conxi
  • Flanagan, Adrienne M.
  • Gorospe, Myriam
  • Ratner, Nancy
  • Aransay, Ana M.
  • Carracedo, Arkaitz
  • Varela Rey, Marta
  • Woodhoo, Ashwin
Cancer cells can develop a strong addiction to discrete molecular regulators, which control the aberrant gene expression programs that drive and maintain the cancer phenotype. Here, we report the identification of the RNA-binding protein HuR/ELAVL1 as a central oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of the Schwann cell lineage. HuR was found to be highly elevated and bound to a multitude of cancer-associated transcripts in human MPNST samples. Accordingly, genetic and pharmacological inhibition of HuR had potent cytostatic and cytotoxic effects on tumor growth, and strongly suppressed metastatic capacity in vivo. Importantly, we linked the profound tumorigenic function of HuR to its ability to simultaneously regulate multiple essential oncogenic pathways in MPNST cells, including the Wnt/beta-catenin, YAP/TAZ, RB/E2F, and BET pathways, which converge on key transcriptional networks. Given the exceptional dependency of MPNST cells on HuR for survival, proliferation, and dissemination, we propose that HuR represents a promising therapeutic target for MPNST treatment.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Hepatic levels of S-adenosylmethionine regulate the adaptive response to fasting

  • Capelo-Diz, Alba
  • Lachiondo-Ortega, Sofía
  • Fernández Ramos, David
  • Cañas-Martín, Jorge
  • Goikoetxea-Usandizaga, Naroa
  • Serrano-Maciá, Marina
  • González-Rellán, María Jesús
  • Mosca, Laura
  • Blázquez-Vicens, Joan
  • Tinahones-Ruano, Alberto
  • Fondevila, Marcos F.
  • Buyan, Mason
  • Delgado, Teresa C.
  • Gutiérrez de Juan, Virginia
  • Ayuso-García, Paula
  • Sánchez-Rueda, Alejandro
  • Velasco-Aviles, Sergio
  • Fernández-Susavila, Héctor
  • Riobello-Suárez, Cristina
  • Dziechciarz, Bartlomiej
  • Montiel-Duarte, Cristina
  • Lopitz-Otsoa, Fernando
  • Bizkarguenaga, Maider
  • Bilbao-García, Jon
  • Bernardo-Seisdedos, Ganeko
  • Senra, Ana
  • Soriano-Navarro, Mario
  • Millet, Óscar
  • Díaz-Lagares, Ángel
  • Crujeiras, Ana B.
  • Bao-Caamano, Aida
  • Cabrera, Diana
  • van Liempd, Sebastiaan M.
  • Borzacchiello, Luigi
  • Gómez-Santos, Beatriz
  • Buqué, Xabier
  • Sáenz de Urturi, Diego
  • Gonzalez-Romero, Francisco
  • Simón, Jorge
  • Rodríguez-Agudo, Rubén
  • Ruiz, Asier
  • Matute, Carlos
  • Beiroa, Daniel
  • Falcón-Pérez, Juan M.
  • Aspichueta, Patricia
  • Rodríguez-Cuesta, Juan
  • Porcelli, Marina
  • Pajares, María Ángeles
  • Ameneiro, Cristina
  • Fidalgo, Miguel
  • Aransay, Ana M.
  • Lama-Diaz, Tomas
  • Blanco, Miguel G.
  • López, Miguel
  • Villa-Bellosta, Ricardo
  • Müller, Timo D.
  • Nogueiras, Rubén
  • Woodhoo, Ashwin
  • Tamayo-Caro, Miguel
  • Martínez-Chantar, María Luz
  • Varela-Rey, Marta
26 p.-6 fig.-1 tab.-1 graph. abst., There has been an intense focus to uncover the molecular mechanisms by which fasting triggers the adaptive cellular responses in the major organs of the body. Here, we show that in mice, hepatic S-adenosylmethionine (SAMe)—the principal methyl donor—acts as a metabolic sensor of nutrition to fine-tune the catabolic-fasting response by modulating phosphatidylethanolamine N-methyltransferase (PEMT) activity, endoplasmic reticulum-mitochondria contacts, β-oxidation, and ATP production in the liver, together with FGF21-mediated lipolysis and thermogenesis in adipose tissues. Notably, we show that glucagon induces the expression of the hepatic SAMe-synthesizing enzyme methionine adenosyltransferase α1 (MAT1A), which translocates to mitochondria-associated membranes. This leads to the production of this metabolite at these sites, which acts as a brake to prevent excessive β-oxidation and mitochondrial ATP synthesis and thereby endoplasmic reticulum stress and liver injury. This work provides important insights into the previously undescribed function of SAMe as a new arm of the metabolic adaptation to fasting., M.V.-R. is supported by Proyecto PID2020-119486RB-100 (funded by MCIN/AEI/10.13039/501100011033), Gilead Sciences International Research Scholars Program in Liver Disease, Acción Estratégica Ciberehd Emergentes 2018 (ISCIII), Fundación BBVA, HORIZON-TMA-MSCA-Doctoral Networks 2021 (101073094), and Redes de Investigación 2022 (RED2022-134485-T). M.L.M.-C. is supported by La CAIXA Foundation (LCF/PR/HP17/52190004), Proyecto PID2020-117116RB-I00 (funded by MCIN/AEI/10.13039/501100011033), Ayudas Fundación BBVA a equipos de investigación científica (Umbrella 2018), and AECC Scientific Foundation (Rare Cancers 2017). A.W. is supported by RTI2018-097503-B-I00 and PID2021-127169OB-I00, (funded by MCIN/AEI/10.13039/501100011033) and by “ERDF A way of making Europe,” Xunta de Galicia (Ayudas PRO-ERC), Fundación Mutua Madrileña, and European Community’s H2020 Framework Programme (ERC Consolidator grant no. 865157 and MSCA Doctoral Networks 2021 no. 101073094). C.M. is supported by CIBERNED. P.A. is supported by Ayudas para apoyar grupos de investigación del sistema Universitario Vasco (IT1476-22), PID2021-124425OB-I00 (funded by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe,” MCI/UE/ISCiii [PMP21/00080], and UPV/EHU [COLAB20/01]). M.F. and M.G.B. are supported by PID2019-105739GB-I00 and PID2020-115472GB-I00, respectively (funded by MCIN/AEI/10.13039/501100011033). M.G.B. is supported by Xunta de Galicia (ED431C 2019/013). C.A., T.L.-D., and J.B.-V. are recipients of pre-doctoral fellowships from Xunta de Galicia (ED481A-2020/046, ED481A-2018/042, and ED481A 2021/244, respectively). T.C.D. is supported by Fundación Científica AECC. A.T.-R. is a recipient of a pre-doctoral fellowship from Fundación Científica AECC. S.V.A. and C.R. are recipients of Margarita Salas postdoc grants under the “Plan de Recuperación Transformación” program funded by the Spanish Ministry of Universities with European Union’s NextGeneration EU funds (2021/PER/00020 and MU-21-UP2021-03071902373A, respectively). T.C.D., A.S.-R., and M.T.-C. are recipients of Ayuda RYC2020-029316-I, PRE2019/088960, and BES-2016/078493, respectively, supported by MCIN/AEI/10.13039/501100011033 and by El FSE invierte en tu futuro. S.L.-O. is a recipient of a pre-doctoral fellowship from the Departamento de Educación del Gobierno Vasco (PRE_2018_1_0372). P.A.-G. is recipient of a FPU pre-doctoral fellowship from the Ministry of Education (FPU19/02704). CIC bioGUNE is supported by Ayuda CEX2021-001136-S financiada por MCIN/AEI/10.13039/501100011033. A.B.-C. was funded by predoctoral contract PFIS (FI19/00240) from Instituto de Salud Carlos III (ISCIII) co-funded by Fondo Social Europeo (FSE), and A.D.-L. was funded by contract Juan Rodés (JR17/00016) from ISCIII. A.B.-C. is a Miguel Servet researcher (CPII22/00008) from ISCIII., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis

  • Palomo Irigoyen, Marta
  • Pérez Andrés, Encarni
  • Iruarrizaga Lejarreta, Marta
  • Barreira Manrique, Adrián
  • Tamayo Caro, Miguel
  • Vila Vecilla, Laura
  • Moreno Cugnon, Leire
  • Beitia, Nagore
  • Medrano, Daniela
  • Fernández Ramos, David
  • Lozano Salvatella, Juan José
  • Okawa, Satoshi
  • Lavín, José L.
  • Martín Martín, Natalia
  • Sutherland, James David
  • Guitiérez de Juan, Virginia
  • González López, Monika
  • Macías Cámara, Nuria
  • Mosén Ansorena, David
  • Laraba, Liyam
  • Hanemann, C. Oliver
  • Ercolano, Emanuela
  • Parkinson, David B.
  • Schultz, Christopher W.
  • Araúzo Bravo, Marcos J.
  • Ascensión, Alex M.
  • Gerovska, Daniela
  • Iribar, Haizea
  • Izeta, Ander
  • Pytel, Peter
  • Krastel, Philipp
  • Provenzani, Alessandro
  • Seneci, Pierfausto
  • Carrasco, Ruben D.
  • Sol, Antonio Del
  • Martínez Chantar, Maria Luz
  • Barrio, Rosa
  • Serra Arenas, Eduard
  • Lázaro García, Conxi
  • Flanagan, Adrienne M.
  • Gorospe, Myriam
  • Ratner, Nancy
  • Aransay, Ana M.
  • Carracedo, Arkaitz
  • Varela Rey, Marta
  • Woodhoo, Ashwin
Cancer cells can develop a strong addiction to discrete molecular regulators, which control the aberrant gene expression programs that drive and maintain the cancer phenotype. Here, we report the identification of the RNA-binding protein HuR/ELAVL1 as a central oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of the Schwann cell lineage. HuR was found to be highly elevated and bound to a multitude of cancer-associated transcripts in human MPNST samples. Accordingly, genetic and pharmacological inhibition of HuR had potent cytostatic and cytotoxic effects on tumor growth, and strongly suppressed metastatic capacity in vivo. Importantly, we linked the profound tumorigenic function of HuR to its ability to simultaneously regulate multiple essential oncogenic pathways in MPNST cells, including the Wnt/beta-catenin, YAP/TAZ, RB/E2F, and BET pathways, which converge on key transcriptional networks. Given the exceptional dependency of MPNST cells on HuR for survival, proliferation, and dissemination, we propose that HuR represents a promising therapeutic target for MPNST treatment.